Skip to main content
SpringerLink
Log in

The Australian Guidelines for Subsidisation of Pharmaceuticals

The Road to Cost-Effective Drug Prescribing?

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Appel LJ, Steinberg EP, Powe NR, Anderson GF, Dwyer SA, et al. Risk reduction from low osmolality contrast media: what do patients think it is worth? Medical Care 28: 324–337, 1990

    Article  PubMed  CAS  Google Scholar 

  • Buchanan JM. Cost and choice: an inquiry in economic theory. Markham Publishing Company, Chicago, 1969

    Google Scholar 

  • Berger MC, Blomquist GC, Kenkel D, Tolley GS. Valuing changes in health risks: a comparison of alternative measures. Southern Economic Journal 53: 967–984, 1987

    Article  Google Scholar 

  • Commonwealth of Australia. Draft guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits committee, including submissions involving economic analyses. Department of Health, Housing and Community Services, Canberra, 1990

    Google Scholar 

  • Cooper BS, Rice DP. The economic cost of illness revisited. Social Security Bulletin 39: 21–36, 1976

    PubMed  CAS  Google Scholar 

  • Cummings RG, Brookshire DS, Schulze WD. Valuing environmental goods. Rowman & Allanheld, New Jersey, 1986

    Google Scholar 

  • Donaldson C. Willingness to pay for publicly provided goods: a possible measure of benefit? Journal of Health Economics 9: 103–118, 1990

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Economic evaluation and the rational diffusion and use of health technologies. Health Policy 7: 309–324, 1987

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Australian guidelines for cost-effectiveness analysis of pharmaceuticals: the thin end of the boomerang? University of York, Centre for Health Economics. Discussion Paper 88, 1991

    Google Scholar 

  • Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, 1987

    Google Scholar 

  • Evans D, Freund D, Dittus R, Robertson J, Henry D. The use of economic analysis as a basis for inclusion of pharmaceutical products on the pharmaceutical benefits scheme. Department of Health, Housing and Community Services, Commonwealth of Australia, Canberra, 1990

    Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1: 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M. Buchanan’s opportunity cost concept. the contingent valuation method and cost-benefit analysis. Journal des Economistes et des Etudes Humaines 2: 123–133, 1991

    Google Scholar 

  • Johannesson M. Economic evaluation of lipid lowering: a feasibility test of the contingent valuation approach. Health Policy 20: 309–320, 1992

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M, Fagerberg B. A health economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension, in press, 1992

    Google Scholar 

  • Johannesson M, Johansson P-O, Jönsson B. Economic Evaluation of drug therapy: a review of the contingent valuation method. PharmacoEconomics 1: 325–337, 1992

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M, Jönsson B. Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 17: 1–23, 1991a

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 19: 55–78, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M, Jönsson B, Borgquist L. Willingness to pay for antihypertensive therapy: results of a Swedish pilot study. Journal of Health Economics 10: 461–474, 1991a

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M, Åberg H, Agréus L, Borgquist L, Jönsson B. Cost-benefit analysis of non-pharmacological treatment of hypertension. Journal of Internal Medicine 230: 307–312, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Johansson P-O. An introduction to modem welfare economics. Cambridge University Press, Cambridge, 1991

    Book  Google Scholar 

  • Loomes G, McKenzie L. The use of QALYs in health care decision making. Social Science and Medicine 28: 299–308, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mehrez A, Gafni A. Quality-adjusted life years, utility theory and healthy-years equivalents. Medical Decision Making 9: 142–149, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mehrez A, Gafni A. The healthy years equivalents: how to measure them using the standard gamble approach. Medical Decision Making 11: 140–146, 1991

    Article  PubMed  CAS  Google Scholar 

  • Mishan EJ. Evaluation of life and limb: a theoretical approach. Journal of Political Economy 79: 687–705, 1971

    Article  Google Scholar 

  • Mishan EJ. Cost-benefit analysis, 2nd ed., Praeger, New York. 1976

    Google Scholar 

  • Mitchell RC, Carson RT. Using surveys to value public goods. Resources for the Future, Washington, D.C., 1989

    Google Scholar 

  • Russel L. Is prevention beller than cure? Brookings Institution, Washington, D.C., 1986

    Google Scholar 

  • Schelling TC. The life you save may be your own. In Chase SB (Ed.) Problems in public expenditure analysis. Brookings Institution, Washington, D.C., 1968

    Google Scholar 

  • Thompson MS. Willingness to pay and accept risks to cure chronic disease. American Journal of Public Health 76: 392–396, 1986

    Article  PubMed  CAS  Google Scholar 

  • Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. Journal of Public Economics 2: 147–157, 1973

    Article  Google Scholar 

  • Weinstein MC. Principles of cost-effective resource allocation in health care organisations. International Journal of Technology Assessment in Health Care 6: 93–103, 1990

    Article  PubMed  CAS  Google Scholar 

  • Weisbrod B. Economics of public health. University of Pennsylvania Press, 1961

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden

    Magnus Johannesson

  2. Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA

    Magnus Johannesson

Authors
  1. Magnus Johannesson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johannesson, M. The Australian Guidelines for Subsidisation of Pharmaceuticals. PharmacoEconomics 2, 355–362 (1992). https://doi.org/10.2165/00019053-199202050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202050-00003

Keywords

Search

Navigation